Description: ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and AMFIA. It is developing therapies targeting misfolded, neurotoxic forms of Amyloid beta in AD and superoxide dismutase 1 (SOD1) in ALS. The Company focuses to use its platform to discover further targets for precision medicine solutions through identification of target epitopes on other misfolded strains of Amyloid beta. The Company focuses to evaluate targets on misfolded strains of tau, another protein implicated in neurodegenerative diseases, including Alzheimer's. The Company has not generated any product revenues.
Home Page: www.promisneurosciences.com
PMN Technical Analysis
1920 Yonge Street
Toronto,
ON
M4S 3E2
Canada
Phone:
416 847 6898
Officers
| Name | Title |
|---|---|
| Dr. Neil R. Cashman M.D. | Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director |
| Mr. Daniel E. Geffken M.B.A., MBA | Chief Financial Officer |
| Mr. Gavin T. Malenfant | Chief Operating Officer |
| Dr. Johanne Kaplan Ph.D. | Chief Devel. Officer |
| Dr. Gail M. Farfel Ph.D. | Chief Exec. Officer |
| Dr. Ernest D. Bush Ph.D. | Head of Pharmacology/Toxicology & Sr. Consultant |
| Dr. David Wishart Ph.D. | Chief Physics Officer |
| Mr. Dennis Chen Ph.D. | Head of Manufacturing & Sr. Consultant |
| Dr. Larry Douglas Altstiel M.D., Ph.D. | Chief Medical Officer |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 56.4881 |
| Price-to-Sales TTM: | 7003.726 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |